TORONTO--(BUSINESS WIRE)--April 12, 2006--Biovail Corporation (NYSE:BVF - News; TSX:BVF - News) announced today that Wellbutrin® XL, the first once-daily extended-release formulation of bupropion hydrochloride approved for the Canadian market for the treatment of depression in adults, has been officially launched and is commercially available.
